Offering integrated artificial intelligence (AI) and seamless multi-nuclei imaging capabilities, the new magnetic resonance imaging (MRI) system reportedly enhances image quality and workflow efficiency.
Philips has garnered 510(k) clearance from the Food and Drug Administration (FDA) for the new MR 7700 3.0T MR system, which enables radiologists to obtain six different clinically relevant nuclei across anatomies.
In addition to seamless integration of multi-nuclei capabilities for enhanced anatomical and metabolic/functional imaging, the MR 7700 system reportedly achieves 20 percent more functional magnetic resonance imaging (fMRI) volume and 50 percent more diffusion tensor imaging (DTI) directions, facilitating an improved level of detail with high-resolution images, according to Philips.
The company adds that the system’s XP gradient coils allow radiologists to reduce scanning times by 35 percent and bolster signal-to-noise ratios by up to 35 percent.
“The low effort required for modifying scan parameters and protocols supports fast and easy experimentation with imaging techniques,” noted Walter Heindel, MD, a professor of radiology and chairman of the Department of Radiology at the University Hospital Münster in Germany. “These latest features clearly help improve our patient and staff experience.”
Philips said the system’s combination of ultra-high gradients and artificial intelligence (AI)-powered patient sensing and motion detection gives radiologists a unique tool to help address increased imaging volume and expectations.
“Enhanced with ultra-high gradients and artificial intelligence, Philips MR 7700 is built to deliver on the high-quality clinical performance expectations of today, and to facilitate the most demanding and promising research programs that will help drive the future of MR imaging, without sacrificing workflow efficiency or wide-bore patient comfort,” said Arjen Radder, the general manager of Magnetic Resonance and Diagnostic X-ray at Philips.
Large CT Study Shows Benefits of AI in Predicting CV Risks in Patients Without Obstructive CAD
June 3rd 2024An AI algorithm that incorporates scoring of coronary inflammation based on coronary CT angiography (CCTA) may enhance long-term cardiovascular risk stratification beyond conventional risk factor and imaging assessments, even in patients without obstructive CAD.
CT-Based AI Model May Enhance Prediction of Lung Cancer Recurrence
May 30th 2024An AI model that includes extracted radiomic features from CT scans more than doubled the sensitivity rate for preoperative prediction of lung cancer recurrence in comparison to traditional TNM staging, according to study findings to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Qure.ai to Debut Multimodality AI Platform for Lung Cancer Imaging at ASCO 2024
May 29th 2024In addition to detecting missed lung nodules on X-rays, the AI-powered Qure.ai lung cancer continuum platform reportedly automates lung nodule measurement on CT scans and facilitates multimodality reporting.